Necrotizing Enterocolitis Global Market Report 2025
상품코드:1730960
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
괴사성 장염 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 복합 연간 성장률(CAGR) 6.4%로 성장할 전망이며, 66억 2,000만 달러로 성장이 예측됩니다. 향후 전망으로는 헬스케어 비용 증가, 궤양성 대장염(UC)의 이환율 및 유병률 상승, 소화기 질환 증가, 노년 인구 및 비만 인구 증가, 고령자층 확대와 같은 요인이 예측 기간 중 성장을 견인할 것으로 생각됩니다. 예측 기간 동안 예상되는 주요 동향으로는 NEC 조기 발견을 위한 바이오마커 연구의 발전, 비침습적 검사법의 진보, 고도 모니터링 시스템의 채택, 수술 기술의 향상, 표적 요법의 개발 등이 있습니다.
조산아수 증가가 괴사성 장염(NEC) 시장의 성장을 견인할 것으로 예측됩니다. 미숙아 출산(조산)은 일반적인 임신기간이 40주인데 반해 임신 37주 미만으로 출산되는 경우에 발생합니다. 조산아의 증가는 조산의 위험을 높이는 고혈압, 당뇨병, 감염증 등의 어머니의 건강상태 및 흡연, 약물 사용, 영양불량 등의 라이프스타일 요인에 기인하고 있습니다. 미숙아는 소화기계가 발달하지 않아 염증이나 감염병에 걸리기 쉽고 괴사성 장염의 영향을 받기 쉽습니다. 예를 들어 2024년 1월 미국 질병예방관리센터는 미숙아 출산이 미국 연간 전체 출생의 8.67%를 차지한다고 보고했습니다. 그 결과 조산아의 증가가 NEC 시장의 성장에 기여하고 있습니다.
괴사성 장염 시장 각사는 미숙아에 있어서 효과적인 치료법이라는 중대한 미충족 요구에 대응하기 위해 혁신적인 치료법의 개발에 주력하고 있습니다. 이러한 해결책 중 하나가 무세포 무균생물학적 제제이며 배양세포 유래 단백질, 성장인자, 사이토카인 등 생리활성 분자를 포함한 정제된 무균 액체이지만 손상되지 않은 세포는 포함되어 있지 않습니다. 이러한 생물학적 제제는 치유를 촉진하고 염증을 억제하도록 설계되어 있습니다. 예를 들면, 2023년 12월, 미국을 거점으로 하는 바이오 의약품 회사 Noveome Biotherapeutics, Inc.는, 미숙아의 NEC를 표적으로 하는 신규 생물학적 제제 ST266의 제1-2상 임상시험을 진행시키는 승인을 미국 식품의약국으로부터 취득했습니다. 이는 ST266이 30년 이상 만에 NEC의 주요 치료제로 개발될 전망이며, 취약한 사람들 사이에서 NEC와 관련된 높은 이환율과 사망률을 고려할 때 매우 중요한 요구에 대응하는 것이기 때문에 중요한 진전이 됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 괴사성 장염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 괴사성 장염 시장 : 성장률 분석
세계의 괴사성 장염 시장 실적 : 규모 및 성장(2019-2024년)
세계의 괴사성 장염 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 괴사성 장염 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 괴사성 장염 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
완전정맥영양(TPN)
위장 감압
항균 요법
항진균 요법
천자
기타 치료법
세계의 괴사성 장염 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
임상 검사
화상 기술
세계의 괴사성 장염 시장 : 스테이지별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
스테이지 I(괴사성 장염 의심)
스테이지 II(확정적 괴사성 장염)
스테이지 III(진행한 괴사성 장염)
세계의 괴사성 장염 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
직접 입찰
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 괴사성 장염 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
신생아 집중 치료실(NICU)
전문 클리닉
세계의 괴사성 장염 시장 : 완전 정맥 영양(TPN) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
표준 TPN 제형
맞춤형 및 개별화 TPN 솔루션
TPN용 지질 유제
TPN에서 단백질 및 아미노산 보충제
미량 영양소 및 전해질 강화 TPN
세계의 괴사성 장염 시장 : 위장 감압술 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
경비위관(NG튜브)의 감압
경구 위관 감압술
감압을 위한 외과적 위 누조설술
비외과적 감압법
세계의 괴사성 장염 시장 : 항균 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
광역 스펙트럼 항생제
그람 양성균 피복 항생제
그람 음성균에 대한 항생제
항생제 병용요법
고위험 신생아에 대한 예방적 항생제 전략
세계의 괴사성 장염 시장 : 항진균 요법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
전신 항진균 요법
조산아에 대한 예방적 항진균 요법
중증 NEC에 대한 항진균제 및 항생제 병용 요법
세계의 괴사성 장염 시장 : 천자 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
진단적 천자
치료적 천자
초음파 및 방사선 기술을 이용한 가이드 하천자
세계의 괴사성 장염 시장 : 기타 치료법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
NEC 예방을 위한 프로바이오틱스 및 프리바이오틱스
외과적 개입
줄기세포요법 및 재생의료의 접근
면역조절요법
지지요법
제7장 지역별 및 국가별 분석
세계의 괴사성 장염 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 괴사성 장염 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
괴사성 장염 시장 : 경쟁 구도
괴사성 장염 시장 : 기업 프로파일
Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
Astellas Pharma Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Mayo Foundation for Medical Education and Research : 개요, 제품 및 서비스, 전략 및 재무 분석
Cleveland Clinic : 개요, 제품 및 서비스, 전략 및 재무 분석
Boston Children's Hospital : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Hollister Incorporated
UPMC Children's Hospital of Pittsburgh
Prolacta Bioscience Inc.
Evolve BioSystems
Sigma-Tau Pharmaceuticals
Mead Johnson & Company LLC
Liminal BioSciences Inc.
Noveome Biotherapeutics Inc.
Infant Bacterial Therapeutics
Prometic Life Sciences Inc.
Nexilico
Siolta Therapeutics
ProThera Biologics Inc.
Plakous Therapeutics Inc.
Chosen Diagnostics Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
괴사성 장염 시장(2029년) : 새로운 기회를 제공하는 국가
괴사성 장염 시장(2029년) : 새로운 기회를 제공하는 부문
괴사성 장염 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Necrotizing enterocolitis (NEC) is a severe, potentially life-threatening gastrointestinal disorder that primarily affects premature infants. It is characterized by inflammation and tissue death (necrosis) in the intestines, which can lead to complications such as perforation and infection. Common symptoms of NEC include feeding intolerance, abdominal bloating, vomiting, and changes in bowel movements.
The primary treatment options for necrotizing enterocolitis include total parenteral nutrition (TPN), gastrointestinal decompression, antimicrobial therapy, antifungal treatment, paracentesis, and other interventions. TPN provides essential nutrients directly into the bloodstream, allowing the intestines to rest and heal, which is particularly beneficial for infants with NEC. Diagnosis involves various laboratory tests and imaging techniques across multiple stages stage I (suspected NEC), stage II (definite NEC), and stage III (advanced NEC). These treatments are distributed through several channels, such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and more, and are used in settings such as hospitals, neonatal intensive care units (NICUs), and specialty clinics.
The necrotizing enterocolitis market research report is one of a series of new reports from The Business Research Company that provides necrotizing enterocolitis market statistics, including the necrotizing enterocolitis industry global market size, regional shares, competitors with the necrotizing enterocolitis market share, detailed necrotizing enterocolitis market segments, market trends, and opportunities, and any further data you may need to thrive in the necrotizing enterocolitis industry. This necrotizing enterocolitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The necrotizing enterocolitis market size has grown strongly in recent years. It will grow from $4.83 billion in 2024 to $5.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth observed during the historic period can be attributed to factors such as the rising incidence of necrotizing enterocolitis, growing populations, higher per capita income, increased government funding, and a rise in premature births.
The necrotizing enterocolitis market size is expected to see strong growth in the next few years. It will grow to $6.62 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. Looking ahead, the growth during the forecast period can be driven by factors such as increasing healthcare costs, the rising incidence and prevalence of ulcerative colitis (UC), the growing number of gastrointestinal diseases, the increase in geriatric and obese populations, and the expanding elderly demographic. Key trends expected in the forecast period include advancements in biomarker research for early NEC detection, progress in non-invasive testing methods, adoption of advanced monitoring systems, improvements in surgical techniques, and the development of targeted therapies.
The rising number of premature births is expected to drive the growth of the necrotizing enterocolitis (NEC) market. Premature births, or preterm births, occur when a baby is delivered before 37 weeks of gestation, compared to the typical 40-week term. The increase in premature births is attributed to maternal health conditions such as high blood pressure, diabetes, and infections, which elevate the risk of preterm labor, as well as lifestyle factors such as smoking, drug use, and poor nutrition. Premature infants are more vulnerable to necrotizing enterocolitis because their gastrointestinal systems are underdeveloped, making them more susceptible to inflammation and infection. For example, in January 2024, the Centers for Disease Control and Prevention reported that premature births account for 8.67% of all births in the U.S. annually. As a result, the rise in premature births is contributing to the growth of the NEC market.
Companies in the necrotizing enterocolitis market are focusing on developing innovative treatments to address the critical unmet needs for effective therapies in premature infants. One such solution is cell-free sterile biologic solutions, which are purified, sterile liquids containing bioactive molecules such as proteins, growth factors, and cytokines derived from cultured cells but without intact cells. These biologic solutions are designed to promote healing and reduce inflammation. For instance, in December 2023, Noveome Biotherapeutics, Inc., a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration to proceed with a Phase 1-2 clinical trial for ST266, a novel biologic targeting NEC in premature infants. This marks a significant advancement, as ST266 is expected to be the first major therapeutic development for NEC in over three decades, addressing a critical need given the high morbidity and mortality rates associated with the disease among vulnerable populations.
In January 2025, Siolta Therapeutics, a U.S.-based developer of novel live biotherapeutics for NEC, partnered with Cowellnex Co. to combat the disease in premature infants. This collaboration combines Siolta's expertise in microbial science with Cowellnex's strength in microbiome drug discovery. By leveraging Siolta's Precision Symbiotics Platform, the partnership aims to advance research and develop treatments for NEC in premature infants. Cowellnex Co. Ltd. is a biotechnology company focused on advancing microbiome drug discovery.
Major players in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children's Hospital, Hollister Incorporated, UPMC Children's Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.
North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in necrotizing enterocolitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the necrotizing enterocolitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The necrotizing enterocolitis market consists of revenues earned by entities providing services such as neonatal intensive care, nutritional support, medical monitoring and support, and parental counseling and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The necrotizing enterocolitis market also includes sales of feeding tubes, surgical instruments for resection, and anti-inflammatory drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Necrotizing Enterocolitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on necrotizing enterocolitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for necrotizing enterocolitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The necrotizing enterocolitis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Total Parenteral Nutrition (TPN); Gastrointestinal Decompression; Antimicrobial Therapy; Antifungal Treatment; Paracentesis; Other Treatments
2) By Diagnosis: Laboratory Tests; Imaging Techniques
3) By Stage: Stage I (Suspected Necrotizing Enterocolitis); Stage II (Definite Necrotizing Enterocolitis); Stage III (Advanced Necrotizing Enterocolitis)
4) By Distribution Channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-User: Hospitals; Neonatal Intensive Care Units (NICUs); Specialty Clinics
Subsegments:
1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations; Customized Or Individualized TPN Solutions; Lipid Emulsions for TPN; Protein And Amino Acid Supplements In TPN; Micronutrient And Electrolyte-Enhanced TPN
2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression; Orogastric Tube Decompression; Surgical Gastrostomy for Decompression; Non-Surgical Decompression Techniques
4) By Antifungal Treatment: Systemic Antifungal Therapy; Prophylactic Antifungal Therapy For Preterm Infants; Combination Antifungal And Antibiotic Therapy For Severe NEC
5) By Paracentesis: Diagnostic Paracentesis; Therapeutic Paracentesis; Guided Paracentesis using Ultrasound Or Radiological Techniques
6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention; Surgical Interventions; Stem Cell Therapy And Regenerative Medicine Approaches; Immunomodulatory Therapies; Supportive Care
Companies Mentioned: Abbott Laboratories; Astellas Pharma Inc.; Mayo Foundation for Medical Education and Research; Cleveland Clinic; Boston Children's Hospital
3. Necrotizing Enterocolitis Market Trends And Strategies
4. Necrotizing Enterocolitis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Necrotizing Enterocolitis Growth Analysis And Strategic Analysis Framework
5.1. Global Necrotizing Enterocolitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Necrotizing Enterocolitis Market Growth Rate Analysis
5.4. Global Necrotizing Enterocolitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Necrotizing Enterocolitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Necrotizing Enterocolitis Total Addressable Market (TAM)
6. Necrotizing Enterocolitis Market Segmentation
6.1. Global Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Total Parenteral Nutrition (TPN)
Gastrointestinal Decompression
Antimicrobial Therapy
Antifungal Treatment
Paracentesis
Other Treatments
6.2. Global Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Laboratory Tests
Imaging Techniques
6.3. Global Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stage I (Suspected Necrotizing Enterocolitis)
Stage II (Definite Necrotizing Enterocolitis)
Stage III (Advanced Necrotizing Enterocolitis)
6.4. Global Necrotizing Enterocolitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct Tender
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Distribution Channels
6.5. Global Necrotizing Enterocolitis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Neonatal Intensive Care Units (NICUs)
Specialty Clinics
6.6. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Total Parenteral Nutrition (TPN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Standard TPN Formulations
Customized Or Individualized TPN Solutions
Lipid Emulsions for TPN
Protein And Amino Acid Supplements In TPN
Micronutrient And Electrolyte-Enhanced TPN
6.7. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Gastrointestinal Decompression, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nasogastric Tube (NG Tube) Decompression
Orogastric Tube Decompression
Surgical Gastrostomy for Decompression
Non-Surgical Decompression Techniques
6.8. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Antimicrobial Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Broad-Spectrum Antibiotics
Gram-Positive Coverage Antibiotics
Gram-Negative Coverage Antibiotics
Combination Antibiotic Therapy
Prophylactic Antibiotic Strategies For High-Risk Neonates
6.9. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Antifungal Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Systemic Antifungal Therapy
Prophylactic Antifungal Therapy For Preterm Infants
Combination Antifungal And Antibiotic Therapy For Severe NEC
6.10. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Paracentesis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostic Paracentesis
Therapeutic Paracentesis
Guided Paracentesis using Ultrasound Or Radiological Techniques
6.11. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Probiotics And Prebiotics for NEC Prevention
Surgical Interventions
Stem Cell Therapy And Regenerative Medicine Approaches
Immunomodulatory Therapies
Supportive Care
7. Necrotizing Enterocolitis Market Regional And Country Analysis
7.1. Global Necrotizing Enterocolitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Necrotizing Enterocolitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
